Piper Jaffray Covers Adverum Biotechnologies (ADVM) with $12.0000 Target; Macquarie Group LTD Has Trimmed Its Marriott Intl New (MAR) Holding

May 20, 2018 - By Adrian Erickson

Marriott International, Inc. (NASDAQ:MAR) Logo

Piper Jaffray analyst initiated coverage on Adverum Biotechnologies (ADVM) with a $12.0000 target and Buy rating. The target indicates a potential upside of 96.72% from firm’s last price.

Macquarie Group Ltd decreased Marriott Intl Inc New (MAR) stake by 27.49% reported in 2017Q4 SEC filing. Macquarie Group Ltd sold 30,418 shares as Marriott Intl Inc New (MAR)’s stock rose 1.21%. The Macquarie Group Ltd holds 80,214 shares with $10.66M value, down from 110,632 last quarter. Marriott Intl Inc New now has $48.95B valuation. The stock increased 0.17% or $0.23 during the last trading session, reaching $138.52. About 1.22 million shares traded. Marriott International, Inc. (NASDAQ:MAR) has risen 45.53% since May 20, 2017 and is uptrending. It has outperformed by 33.98% the S&P500.

More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Nasdaq.com which released: “Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st …” on May 18, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on May 18, 2018, Nasdaq.com published: “Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD” on May 01, 2018. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” published on May 18, 2018 as well as 247Wallst.com‘s news article titled: “Top Analyst Upgrades and Downgrades: Aimmune, Anadarko, Carrizo, Mastercard, PayPal, Spotify, Visa and More” with publication date: May 18, 2018.

Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on August, 14. They expect $-0.30 EPS, down 11.11% or $0.03 from last year’s $-0.27 per share. After $-0.30 actual EPS reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $379.86 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

Among 4 analysts covering Adverum Biotec… (ADVM), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Adverum Biotec… has $12.0 highest and $3.5 lowest target. $7.17’s average target is 17.54% above currents $6.1 stock price. Adverum Biotec… had 6 analyst reports since June 8, 2016 according to SRatingsIntel. The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) earned “Buy” rating by Raymond James on Thursday, October 12. The rating was initiated by Piper Jaffray on Friday, May 18 with “Buy”. The stock has “Neutral” rating by Chardan Capital Markets on Wednesday, June 8. On Thursday, February 15 the stock rating was initiated by Piper Jaffray with “Buy”.

The stock increased 1.67% or $0.1 during the last trading session, reaching $6.1. About 873,503 shares traded. Adverum Biotechnologies, Inc. (ADVM) has risen 103.64% since May 20, 2017 and is uptrending. It has outperformed by 92.09% the S&P500.

Since December 8, 2017, it had 1 insider purchase, and 10 selling transactions for $30.92 million activity. Harrison Deborah Marriott also sold $4.56M worth of Marriott International, Inc. (NASDAQ:MAR) shares. $7.24M worth of Marriott International, Inc. (NASDAQ:MAR) was sold by McPherson Amy. Smith Craig S. sold $2.03 million worth of Marriott International, Inc. (NASDAQ:MAR) on Tuesday, March 20. Rodriguez David A had sold 7,600 shares worth $1.01 million. The insider Marriott Stephen Blake sold $143,828. 250 Marriott International, Inc. (NASDAQ:MAR) shares with value of $35,368 were bought by SCHWAB SUSAN C. $1.12 million worth of stock was sold by DUNCAN BRUCE W on Wednesday, December 13.

More notable recent Marriott International, Inc. (NASDAQ:MAR) news were published by: Bizjournals.com which released: “Marriott family drama: A big stock gift as father, son look to settle lawsuit” on May 16, 2018, also Streetinsider.com with their article: “Marriott International (MAR) PT Raised to $150 at Morgan Stanley” published on May 18, 2018, Bizjournals.com published: “Marriott-brand hotels sprouting next to Topgolf, on Nashville’s east bank of Cumberland River” on April 30, 2018. More interesting news about Marriott International, Inc. (NASDAQ:MAR) were released by: Investorplace.com and their article: “3 Stocks to Watch on Wednesday: Apple Inc. (AAPL), Marriott International Inc (MAR) and Monster Beverage Corp …” published on May 09, 2018 as well as Bizjournals.com‘s news article titled: “Leaders call for regional approach to Charlotte transit — but funding, political hurdles remain” with publication date: May 18, 2018.

Macquarie Group Ltd increased Home Bancorp Inc (NASDAQ:HBCP) stake by 7,195 shares to 7,620 valued at $329,000 in 2017Q4. It also upped Tetra Tech Inc New (NASDAQ:TTEK) stake by 63,040 shares and now owns 746,162 shares. Osi Systems Inc (NASDAQ:OSIS) was raised too.

Among 20 analysts covering Marriott International (NASDAQ:MAR), 11 have Buy rating, 0 Sell and 9 Hold. Therefore 55% are positive. Marriott International had 65 analyst reports since August 5, 2015 according to SRatingsIntel. Robert W. Baird maintained the stock with “Neutral” rating in Friday, November 10 report. The firm earned “Buy” rating on Tuesday, November 7 by RBC Capital Markets. Stifel Nicolaus maintained Marriott International, Inc. (NASDAQ:MAR) rating on Wednesday, November 8. Stifel Nicolaus has “Hold” rating and $115 target. On Thursday, April 19 the stock rating was maintained by Robert W. Baird with “Hold”. The stock of Marriott International, Inc. (NASDAQ:MAR) earned “Hold” rating by Stifel Nicolaus on Tuesday, October 10. The rating was downgraded by Barclays Capital to “Overweight” on Wednesday, August 12. The stock of Marriott International, Inc. (NASDAQ:MAR) earned “Buy” rating by RBC Capital Markets on Friday, September 22. The company was downgraded on Monday, November 28 by Evercore. On Tuesday, October 17 the stock rating was maintained by Robert W. Baird with “Hold”. The firm has “Hold” rating by Evercore given on Wednesday, August 5.

Marriott International, Inc. (NASDAQ:MAR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: